FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
about
CIViC databaseFBXW7 expression is associated with prognosis and chemotherapeutic outcome in Chinese patients with gastric adenocarcinomaMolecular genetics complexity impeding research progress in breast and ovarian cancers.FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.From genotype to functional phenotype: unraveling the metabolomic features of colorectal cancer.Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients.Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion.Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases.Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape.Genetic mutations in human rectal cancers detected by targeted sequencing.The importance of regulatory ubiquitination in cancer and metastasis.Subclonal diversity arises early even in small colorectal tumours and contributes to differential growth fates.Molecular characterization of oral squamous cell carcinoma using targeted next-generation sequencing.Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinicsFBXW7: a critical tumor suppressor of human cancers
P2860
Q27612411-952D1907-974E-4A86-B20F-823AEF5B7466Q33630452-45C7E229-7FD9-4587-B51F-4380A851FC12Q33858073-2CF829E5-9A96-4267-9F4E-2B24DAAAC811Q33889158-AE7F24F2-3D7E-48E1-B614-B2D3CD95100AQ34347646-DDB91B07-C0FA-40EB-A730-6E80A890A73CQ35995839-F44159A2-D44F-4144-9508-AB4172642F63Q36167042-7A46942F-BDF6-4C20-A1EE-8A6FEC8890C3Q36304519-2C977683-93E1-42AF-83D4-1C7E2EDAB9DEQ36382681-24DDC2EA-1007-4AC5-853A-9AAC98251332Q37282490-06C649A2-C113-4CBE-8406-03FF968AF29CQ38297206-7B0130A4-937E-4F43-A7AF-AE8074A1561CQ38372535-DD85F204-4CDD-4BEB-A1F5-BC23E4F208A7Q38989186-D968CAFF-B364-4638-877E-01294AA461B9Q39122602-BF3DD0E2-0ABF-4039-A2EF-6B807E3A9D68Q39408419-6DE6B4D5-0D2F-446B-83F5-4E5CECDF30C5Q50440575-14AF178A-0439-417E-9B27-C029C9413633Q55209571-7998728D-E383-4114-9286-3F520BAD8622Q58101254-632BB1C8-A1C3-43D3-9A74-EE495E060C69Q58797685-15FF09B2-E87F-494A-9E6A-F7FE39250D8C
P2860
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
FBXW7 mutations in patients wi ...... outcomes with mTOR inhibitors.
@ast
FBXW7 mutations in patients wi ...... outcomes with mTOR inhibitors.
@en
FBXW7 mutations in patients wi ...... outcomes with mTOR inhibitors.
@nl
type
label
FBXW7 mutations in patients wi ...... outcomes with mTOR inhibitors.
@ast
FBXW7 mutations in patients wi ...... outcomes with mTOR inhibitors.
@en
FBXW7 mutations in patients wi ...... outcomes with mTOR inhibitors.
@nl
altLabel
FBXW7 Mutations in Patients wi ...... Outcomes with mTOR Inhibitors
@en
prefLabel
FBXW7 mutations in patients wi ...... outcomes with mTOR inhibitors.
@ast
FBXW7 mutations in patients wi ...... outcomes with mTOR inhibitors.
@en
FBXW7 mutations in patients wi ...... outcomes with mTOR inhibitors.
@nl
P2093
P2860
P50
P3181
P1433
P1476
FBXW7 mutations in patients wi ...... outcomes with mTOR inhibitors.
@en
P2093
David S Hong
Denis L Jardim
Jennifer J Wheler
Kenneth Hess
Ralph Zinner
Sarina A Piha-Paul
Shannon N Westin
Sinchita Roy-Chowdhuri
Vivek Subbiah
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0089388
P407
P577
2014-01-01T00:00:00Z